Zura Bio Limited (ZURA) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $5.25: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: Below-average business quality.
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize... Read more
Sell if holding. Engine safety override at $5.25: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.7/10, moderate confidence.
Passes 6/7 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 40d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Recent developments
updated 2026-07-05Recent Developments — Zura Bio Limited
Latest news
- NEWS Wedbush Reiterates Outperform on Zura Bio, Maintains $15 Price Target — benzinga Jul 1, 2026 positive
- NEWS Zura Bio Completes Enrollment In Phase 2 TibuSHIELD Trial of Tibulizumab in Adults With HS — benzinga Jun 29, 2026 positive
Generated 2026-07-05T10:00:59Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $5.25: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $4.81. Score 4.7/10, moderate confidence.
Take-profit target: $5.89 (+13.9% upside). Prior stop was $4.81. Stop-loss: $4.81.
DATA_ISSUE: analyst_target_implausible (raw $15.67 vs price $5.17 — ratio 3.0×). Rejected, falling back to technical TP.; Quality below floor (1.2 < 4.0).
Zura Bio Limited trades at a P/E of N/A (forward -51.7). TrendMatrix value score: 5.0/10. Verdict: Sell.
14 analysts cover ZURA with a consensus score of 4.4/5. Average price target: $16.
What does Zura Bio Limited do?Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders...
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.